Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB
Winckler JL, Schaaf HS, Draper HR, McIlleron H, Norman J, van der Laan LE, Wiesner L, Donald PR, et al. (10 authors)
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021-11
Abstract
BACKGROUND: High-dose isoniazid (INH H ) (15-20 mg/kg/day) could be administered to overcome low-level INH resistance, but pharmacokinetic data are sparse. METHODS: This observational study included South African children ( H as preventive therapy, or treatment for multidrug-resistant TB (MDR-TB) exposure or disease. Pharmacokinetic sampling was performed after an INH dose of 20 mg/kg. Non-compartmental analysis and multivariable regression models were used to evaluate associations of key covariates with area under the curve (AUC 0-24 ) and maximum concentration (C max ). AUC and C max values were compared against proposed adult targets. RESULTS: Seventy-seven children were included, with median age of 3.7 years; 51 (66%) had MDR-TB disease and 26 (34%) had MDR-TB exposure. Five were HIV-positive, of whom four were ≥5 years old. The median AUC 0-24 was 19.46 µgh/mL (IQR 10.76-50.06) and C max was 5.14 µg/mL (IQR 2.69-13.2). In multivariable analysis of children aged 0-24 (geometric mean ratio GMR 0.19, 95% CI 0.15-0.26; P max (GMR 0.20, 95% CI 0.15-0.26; P CONCLUSIONS: INH concentrations in children with MDR-TB disease were much lower than expected, but comparable to previous reports in children with MDR-TB exposure. Further studies should confirm these findings and explore possible causes.
MeSH terms
- Humans
- Tuberculosis, Multidrug-Resistant
- Isoniazid
- Antitubercular Agents
- Adult
- Child
- Child, Preschool